Avidity Biosciences Pursues Merger with Novartis and Atrium Stock Distribution Plan
- Avidity Biosciences is merging with Novartis AG and distributing shares from Atrium Therapeutics to enhance shareholder value.
- The special stockholder meeting is rescheduled for February 26, 2026, to meet conditions for Atrium share distribution.
- Avidity aims to innovate RNA therapeutics through Antibody Oligonucleotide Conjugates (AOCs™) as part of its long-term strategy.
Avidity Biosciences Advances Towards Major Merger and Stock Distribution
Avidity Biosciences, Inc. confirms its commitment to enhancing shareholder value through a strategic merger with Novartis AG and the successful distribution of shares from Atrium Therapeutics, Inc. Originally scheduled for February 23, 2026, Avidity’s special meeting of stockholders is promptly convened and adjourned, allowing for the necessary time to satisfy conditions for the distribution of Atrium shares—referred to as "SpinCo" common stock. The meeting is reconvened for February 26, 2026, at 10:00 AM Eastern via a virtual link, enabling shareholders to retain their registration without the need for re-registration.
The adjournment reflects Avidity's strategic planning as it follows through on important merger milestones. The anticipated share distribution of Atrium stock to Avidity shareholders is contingent upon the successful closing of the merger with Novartis, set for February 27, 2026. Both events hinge on satisfying predefined conditions detailed in Avidity’s Definitive Proxy Statement filed on January 30, 2026. The record date for shareholders remains January 29, 2026, underscoring the importance of shareholder participation. To facilitate the transition, Avidity's common stock will temporarily trade under the ticker "RNAM" on the Nasdaq Global Market on the date of the distribution.
Avidity emphasizes its mission to improve patient outcomes through innovative Antibody Oligonucleotide Conjugates (AOCs™), a burgeoning class of RNA therapeutics. The company's strategic maneuvers, including the merger and the share distribution, underscore its long-term vision to enhance its therapeutic portfolio and clinical capabilities. As Avidity navigates the complexities of regulatory requirements and shareholder approvals, it encourages shareholders who have yet to cast their votes to participate in the process, facilitating a clear path towards the company's transformative goals.
Avidity's unique positioning within the RNA therapeutics space places it at the forefront of biotechnology innovation. The upcoming merger with Novartis not only presents significant growth opportunities but also highlights the company's ability to address critical health challenges with cutting-edge therapeutic solutions. With the virtual special meeting set to reconvene, stakeholders remain hopeful for a seamless execution of the planned share distribution and merger, reinforcing Avidity's foundational strategy for sustainable advancements in healthcare.